SCHEDULE: RTW Investments Discloses Stake in Stoke Therapeutics

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 9.9% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• RTW Investments, LP, an investment adviser, and Roderick Wong, its Managing Partner and Chief Investment Officer, have filed a Schedule 13G detailing their beneficial ownership of Stoke Therapeutics, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 5,940,866 shares, representing 9.9% of the company's outstanding common stock.
• This ownership level is calculated assuming the exercise of warrants to purchase 317,341 shares, with the caveat that exercise is limited to maintain beneficial ownership below 9.99% of outstanding shares.
• The filing indicates that the RTW Funds have the right to receive dividends and proceeds from the sale of these shares, with RTW Master Fund Ltd. holding rights to over 5% of the shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating sustained interest and a significant investment by RTW Investments, but without new operational or financial performance data.

Positives

• RTW Investments, LP and Roderick Wong have disclosed a significant ownership stake (9.9%) in Stoke Therapeutics, Inc., indicating confidence in the company's prospects.
• The reporting persons hold shared voting and dispositive power over 5,940,866 shares, giving them substantial influence.
• The filing confirms that the reporting persons are acting in the ordinary course of business and not to influence or change control of the issuer.

Negatives

• The ownership percentage is capped at 9.9% due to warrant exercise limitations, preventing a higher stake even if desired.
• The filing does not provide specific financial performance data for Stoke Therapeutics, Inc., focusing solely on ownership disclosure.

Risks

• The reporting persons cannot exercise all their warrants if doing so would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• Potential for future changes in ownership or investment strategy by RTW Investments, LP could impact Stoke Therapeutics, Inc.'s stock.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It is solely an ownership disclosure.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like RTW Investments often signal conviction in a company's technology or market position, particularly in the biotechnology sector where Stoke Therapeutics operates. Such filings can attract attention from other investors monitoring institutional activity.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by RTW Investments may be viewed positively, potentially indicating confidence in the company's future, but also raises questions about potential future influence or strategic shifts.
• Management: The filing confirms that the reporting persons are not seeking to influence or change control, which may provide a degree of stability.
• Creditors: No direct impact is indicated.

Next Steps

• Monitor future filings from RTW Investments, LP for any changes in their stake or disclosed intentions.
• Observe Stoke Therapeutics, Inc.'s operational and financial performance to assess the underlying value of the investment.

Key Dates

Recommendation

The filing indicates a significant, but not controlling, stake by a known investment firm. Without new operational or financial data from Stoke Therapeutics, Inc. itself, the primary takeaway is the sustained interest from RTW Investments. This warrants a 'hold' recommendation, suggesting investors should maintain their current positions while awaiting further company-specific developments or strategic shifts from the investor.

Keywords

Stoke Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Warrants, SEC Filing